

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: <http://www.elsevier.com/locate/crvasa>

Guidelines

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with EASD. Summary of the document prepared by the Czech Society of Cardiology[☆]



Hana Rosolova^{a,*}, Terezie Pelikanova^b, Zuzana Motovska^c

^a Charles University Prague – Medical Faculty in Pilsen, Czech Republic

^b Institute of Clinical and Experimental Medicine Prague, Czech Republic

^c Faculty Hospital Kralovske Vinohrady Prague, Czech Republic

Authors of the original ESC guidelines document [1]: Lars Rydén, Peter J. Grant, on behalf of ESC Task Force on diabetes, pre-diabetes, and cardiovascular diseases.

ARTICLE INFO

Article history:

Received 19 November 2013

Received in revised form

3 January 2014

Accepted 6 January 2014

Available online 13 March 2014

Keywords:

Diabetes mellitus

Pre-diabetes

Cardiovascular disease

Cardiovascular prevention

Guidelines



EUROPEAN
SOCIETY OF
CARDIOLOGY®



ČESKÁ KARDIOLOGICKÁ SPOLEČNOST
THE CZECH SOCIETY OF CARDIOLOGY

Contents

1. Preamble	e191
2. Introduction	e191
3. Abnormalities of glucose metabolism and cardiovascular disease	e192
3.1. Definition, classification and diagnosis	e192
3.2. Epidemiology	e192
3.3. Screening for disorders of glucose metabolism	e192
3.4. Disorders of glucose metabolism and cardiovascular disease	e193

[☆] For permissions: please e-mail: guidelines@escardio.org.

* Corresponding author. Tel.: +420 377402384; fax: +420 377402650.

E-mail address: rosolova@fnplzen.cz (H. Rosolova).

<http://dx.doi.org/10.1016/j.crvasa.2014.01.007>

0010-8650/© 2014 European Society of Cardiology. All rights reserved. Published by Elsevier Urban & Partner Sp.z.o.o. on behalf of The Czech Society of Cardiology. Open access under [CC BY-NC-ND license](http://creativecommons.org/licenses/by-nc-nd/4.0/).

3.5.	Delaying conversion to type 2 diabetes mellitus	e193
4.	Molecular basis of cardiovascular disease in diabetes mellitus	e193
4.1.	The cardiovascular continuum in diabetes mellitus	e193
4.2.	Pathophysiology of insulin resistance in type 2 diabetes mellitus	e193
4.3.	Endothelial dysfunction, oxidative stress and vascular inflammation	e193
4.4.	Macrophage dysfunction	e193
4.5.	Atherogenic dyslipidaemia	e194
4.6.	Coagulation and platelet function	e194
4.7.	Diabetic cardiomyopathy	e195
4.8.	The metabolic syndrome (MetS)	e195
4.9.	Endothelial progenitor cells and vascular repair	e195
4.10.	Conclusions	e195
5.	Cardiovascular risk assessment in patients with dysglycaemia	e195
5.1.	Risk scores developed for people without diabetes	e195
5.2.	Evaluation of cardiovascular risk in people with pre-diabetes	e195
5.3.	Risk engines developed for people with diabetes	e195
5.4.	Risk assessment based on biomarkers and imaging	e195
5.5.	Gaps in knowledge	e195
6.	Prevention of cardiovascular disease in patients with diabetes	e195
6.1.	Lifestyle	e195
6.2.	Glucose control	e196
6.3.	Blood pressure	e196
6.4.	Dyslipidaemia	e197
6.5.	Platelet function	e198
6.6.	Multifactorial approaches	e198
7.	Management of stable and unstable coronary artery disease in patients with diabetes	e199
7.1.	Optimal medical treatment	e199
7.2.	Revascularization	e199
8.	Heart failure and diabetes	e200
8.1.	Prevalence and incidence of HF in T2DM and T2DM in HF	e200
8.2.	DM and HF morbidity and mortality	e200
8.3.	Pharmacological managements of HF in T2DM	e200
8.4.	Non-pharmacological therapies	e200
8.5.	Glucose-lowering treatment in patients with HF	e200
9.	Arrhythmias: atrial fibrillation and sudden cardiac death	e201
9.1.	Diabetes and atrial fibrillation	e201
9.2.	Sudden cardiac death	e201
10.	Peripheral- and cerebrovascular disease	e201
10.1.	Peripheral artery disease (PAD)	e201
10.2.	Lower extremity artery diseases (LEAD)	e202
10.3.	Carotid artery disease	e202
11.	Microvascular disease in the eyes and kidneys	e203
11.1.	Pathophysiology of microvascular disease	e204
11.2.	Treatment and treatment targets	e204
12.	Patient-centred care	e204
12.1.	General aspects	e204
12.2.	Gaps in knowledge	e205
	References	e205

1. Preamble

This is the second iteration of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) joining forces to write guidelines on the management of the combination of diabetes mellitus (DM), pre-diabetes, and cardiovascular disease (CVD), designed to assist clinicians and other healthcare workers to make evidence based management decisions [1].

2. Introduction

The increasing prevalence of DM worldwide has led to a situation where approximately 360 million people had DM in 2011 (60 million in Europe), of whom more than 95% would have had type 2 DM (T2DM); another 300 million individuals had features indicating future risk of developing T2DM, including fasting hyperglycaemia, impaired glucose tolerance (IGT), gestational DM and euglycaemic insulin resistance (IR).

Download English Version:

<https://daneshyari.com/en/article/5880333>

Download Persian Version:

<https://daneshyari.com/article/5880333>

[Daneshyari.com](https://daneshyari.com)